Absci Corp - 8-K Filing
Absci Corporation reported first-quarter revenue of $0.2 million, down from $1.2 million in the same period last year, with R&D expenses rising to $19.3 million due to clinical development costs for ABS-201 and SG&A expenses at $9.1 million. The company announced progress on its Phase 1/2a trial of ABS-201, including successful dosing in all four healthy volunteer SAD cohorts with favorable safety data and preliminary PK modeling supporting a six-month dosing interval; it also initiated MAD cohort dosing for AGA participants and plans to report initial results by Q2 2026. Additionally, Absci a... (Items: 2.02 Results of Operations and Financial Condition, 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $ABSI